Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Shares Purchased by Barclays PLC

Barclays PLC raised its holdings in shares of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) by 27.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 68,400 shares of the biotechnology company’s stock after buying an additional 14,642 shares during the period. Barclays PLC owned about 0.21% of Concert Pharmaceuticals worth $341,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in CNCE. Acadian Asset Management LLC lifted its position in Concert Pharmaceuticals by 416.6% during the first quarter. Acadian Asset Management LLC now owns 533,573 shares of the biotechnology company’s stock valued at $2,662,000 after buying an additional 430,297 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of Concert Pharmaceuticals by 60.3% during the first quarter. Renaissance Technologies LLC now owns 923,224 shares of the biotechnology company’s stock valued at $4,607,000 after purchasing an additional 347,124 shares during the period. Pura Vida Investments LLC purchased a new stake in shares of Concert Pharmaceuticals during the fourth quarter valued at approximately $3,709,000. Geode Capital Management LLC raised its stake in shares of Concert Pharmaceuticals by 41.2% during the first quarter. Geode Capital Management LLC now owns 538,521 shares of the biotechnology company’s stock valued at $2,687,000 after purchasing an additional 157,154 shares during the period. Finally, Verition Fund Management LLC purchased a new stake in shares of Concert Pharmaceuticals during the fourth quarter valued at approximately $1,683,000. 64.51% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ:CNCE opened at $3.60 on Thursday. The stock has a fifty day moving average of $4.00. The company has a market capitalization of $115.83 million, a price-to-earnings ratio of -1.52 and a beta of 0.49. Concert Pharmaceuticals, Inc. has a 12-month low of $3.35 and a 12-month high of $13.50.

Concert Pharmaceuticals (NASDAQ:CNCE) last issued its quarterly earnings results on Tuesday, May 4th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.01). The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $1.50 million. Concert Pharmaceuticals had a negative return on equity of 59.51% and a negative net margin of 974.15%. As a group, equities analysts predict that Concert Pharmaceuticals, Inc. will post -2.72 earnings per share for the current year.

CNCE has been the topic of a number of analyst reports. HC Wainwright reiterated a “buy” rating and set a $17.00 price objective on shares of Concert Pharmaceuticals in a research note on Friday, July 2nd. Mizuho reiterated a “buy” rating and set a $13.00 price objective on shares of Concert Pharmaceuticals in a research note on Tuesday, May 4th. Finally, Zacks Investment Research upgraded shares of Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, July 7th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $17.80.

About Concert Pharmaceuticals

Concert Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. Its lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition.

Further Reading: Special Purpose Acquisition Company (SPAC) – What You Need to Know

Institutional Ownership by Quarter for Concert Pharmaceuticals (NASDAQ:CNCE)

Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.